AiPD: Autoinhibited Protein Database

O14495

Gene name	PLPP3
Protein name	Phospholipid phosphatase 3
Names	Lipid phosphate phosphohydrolase 3, PAP2-beta, Phosphatidate phosphohydrolase type 2b, Phosphatidic acid phosphatase 2b, PAP-2b, PAP2b, Vascular endothelial growth factor and type I collagen-inducible protein, VCIP
Species	Homo sapiens (Human)
KEGG Pathway	hsa:8613
EC number	3.1.3.4: Phosphoric monoester hydrolases
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

1-52 (Predicted disordered autoinhibitory region) PR

Target domain
Relief mechanism
Assay	cis-regPred

AID

1-52 (Predicted disordered autoinhibitory region)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell Systems, 2, 89-100

Autoinhibited structure

Activated structure

1 structures for O14495

Entry ID	Method	Resolution	Chain	Position	Source
AF-O14495-F1	Predicted				AlphaFoldDB

227 variants for O14495

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
TCGA novel	1	M>?	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA873626 rs759896266	4	Y>C	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
rs1557520015 CA340573388	5	K>R		No	ClinGen Ensembl
rs776566428 CA873625	7	D>N		No	ClinGen ExAC gnomAD
rs1263723798 CA340573368	8	K>Q		No	ClinGen gnomAD
CA873624 rs778010038	12	P>L		No	ClinGen ExAC gnomAD
CA340573340 rs778010038	12	P>Q		No	ClinGen ExAC gnomAD
CA873623 rs778010038	12	P>R		No	ClinGen ExAC gnomAD
CA340573341 rs1002367298	12	P>S		No	ClinGen gnomAD
rs1002367298 CA23075418	12	P>T		No	ClinGen gnomAD
rs1217184180 CA340573327	14	S>T		No	ClinGen gnomAD
rs141567203 CA23075417	15	K>N		No	ClinGen ESP TOPMed gnomAD
rs1340224986 CA340573323	15	K>Q		No	ClinGen gnomAD
TCGA novel	15	K>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs771905409 CA873621	16	N>D		No	ClinGen ExAC gnomAD
CA873620 rs778340556	16	N>K		No	ClinGen ExAC gnomAD
CA340573310 rs1291279581	17	G>S		No	ClinGen gnomAD
rs1418129246 CA340573285	20	P>R		No	ClinGen gnomAD
rs1476732641 CA340573284	21	A>T		No	ClinGen gnomAD
rs1046947891 CA340573267	23	N>K		No	ClinGen TOPMed gnomAD
rs781512827 CA873616	23	N>S		No	ClinGen ExAC gnomAD
CA340573264 rs1282644784	24	N>D		No	ClinGen TOPMed
rs1034600155 CA23075415	25	N>T		No	ClinGen TOPMed
rs1265429227 CA340573245	26	P>L		No	ClinGen TOPMed gnomAD
rs1456547160 CA340573237	28	R>G		No	ClinGen gnomAD
CA340573235 rs1275293647	28	R>K		No	ClinGen TOPMed gnomAD
CA873610 rs763384351	28	R>S		No	ClinGen ExAC TOPMed gnomAD
CA340573234 rs1275293647	28	R>T		No	ClinGen TOPMed gnomAD
rs1184957085 CA340573220	30	G>D		No	ClinGen TOPMed
CA340573212 rs1317720662	31	S>T		No	ClinGen gnomAD
CA340573200 rs1271117158	33	R>W		No	ClinGen TOPMed gnomAD
CA340573193 rs1475072173	34	V>A		No	ClinGen TOPMed
CA340573195 rs1004200015	34	V>L		No	ClinGen gnomAD
CA23075414 rs1004200015	34	V>M		No	ClinGen gnomAD
rs1194898909 CA340573188	35	L>P		No	ClinGen TOPMed
rs752808813 CA873609	36	L>F		No	ClinGen ExAC gnomAD
TCGA novel	41	L>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs370279307 CA873607	42	F>L		No	ClinGen ESP ExAC TOPMed gnomAD
rs1569624054 CA340573134	43	C>F		No	ClinGen Ensembl
CA340573118 rs777046381	45	F>L		No	ClinGen ExAC gnomAD
rs1463706976 CA340573115	46	M>L		No	ClinGen gnomAD
rs1395566830 CA340573113	46	M>T		No	ClinGen gnomAD
rs1349263606 CA340574555	47	A>V	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
CA340574535 rs1312036370	50	P>L		No	ClinGen gnomAD
CA23070801 rs201459952	53	I>M		No	ClinGen 1000Genomes TOPMed
CA23070802 rs375912953	53	I>V		No	ClinGen ESP TOPMed
CA873566 rs202156325	54	I>M		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA340574509 rs1400216670	55	E>K		No	ClinGen gnomAD
TCGA novel	58	T>P	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1207605327 CA340574468	60	K>N		No	ClinGen TOPMed
CA873562 rs767802099	63	H>R		No	ClinGen ExAC
CA340574450 rs1236594942	63	H>Y	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
CA340574444 rs1485987236	64	R>*		No	ClinGen TOPMed
rs749718381 CA23070799	64	R>Q	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
CA340574438 rs1189655666	65	G>E		No	ClinGen TOPMed
rs761474304 CA873561	71	E>K		No	ClinGen ExAC gnomAD
rs780501647 CA23070798	72	S>G		No	ClinGen gnomAD
rs1349242578 CA340574386	72	S>N		No	ClinGen TOPMed gnomAD
CA873560 rs751372035	74	K>N		No	ClinGen ExAC TOPMed gnomAD
rs763962988 CA873559	78	K>Q		No	ClinGen ExAC gnomAD
CA873558 rs762937062	78	K>R		No	ClinGen ExAC TOPMed gnomAD
CA340574328 rs1445945294	81	E>*		No	ClinGen gnomAD
TCGA novel	81	E>D	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA340574302 rs1225164235	84	N>K		No	ClinGen TOPMed gnomAD
CA873556 rs769334962	85	D>N		No	ClinGen ExAC gnomAD
CA23070797 rs982368598	85	D>V		No	ClinGen TOPMed gnomAD
rs1557506920 CA340574293	86	A>S		No	ClinGen Ensembl
CA873552 rs748400164	91	V>M		No	ClinGen ExAC gnomAD
TCGA novel	92	G>missing	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA873548 rs780258727	94	V>A		No	ClinGen ExAC gnomAD
CA873549 rs143533558	94	V>I		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA340574213 rs1421878450	99	A>S		No	ClinGen gnomAD
CA340574214 rs1421878450	99	A>T		No	ClinGen gnomAD
rs190738006 CA873545	99	A>V	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen 1000Genomes ExAC NCI-TCGA TOPMed gnomAD
rs1275053938 CA340574187	101	I>V		No	ClinGen gnomAD
rs1231942061 CA340574180	102	T>A		No	ClinGen gnomAD
rs142369156 CA873526	102	T>M		No	ClinGen ESP ExAC TOPMed gnomAD
rs757418849 CA340574164	104	E>D		No	ClinGen ExAC TOPMed gnomAD
CA873523 rs751819679	106	Y>C		No	ClinGen ExAC TOPMed gnomAD
CA23069471 rs751819679	106	Y>S		No	ClinGen ExAC TOPMed gnomAD
CA340574146 rs1243496213	107	R>P		No	ClinGen TOPMed
rs1243496213 CA340574147	107	R>Q		No	ClinGen TOPMed
rs201684971 CA873521	107	R>W		No	ClinGen ESP ExAC TOPMed gnomAD
CA340574120 rs1172360094	111	L>V		No	ClinGen gnomAD
rs1319646207 CA340574112	112	K>R		No	ClinGen TOPMed
rs140476566 CA873519	114	S>L		No	ClinGen ESP ExAC TOPMed gnomAD
rs200383278 CA873516	115	R>L		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA873515 rs200383278	115	R>Q		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA873517 rs753280597 COSM1667569	115	R>W	lung Variant assessed as Somatic; 0.0 impact. [Cosmic, NCI-TCGA]	No	ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD
CA873514 rs151304097	116	S>A		No	ClinGen ESP ExAC TOPMed gnomAD
rs767309067 CA873513	116	S>L		No	ClinGen ExAC TOPMed gnomAD
rs151304097 CA340574092	116	S>P		No	ClinGen ESP ExAC TOPMed gnomAD
TCGA novel	116	S>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA340574090 rs767309067	116	S>W		No	ClinGen ExAC TOPMed gnomAD
CA873512 rs763340277	117	T>M		No	ClinGen ExAC gnomAD
rs148766697 CA873510	119	Q>H		No	ClinGen ESP ExAC TOPMed gnomAD
CA873509 rs749523087	120	N>I		No	ClinGen ExAC TOPMed gnomAD
CA873506 rs747117364	123	V>M		No	ClinGen ExAC gnomAD
rs758626117 CA873504	124	A>G		No	ClinGen ExAC TOPMed
rs777936496 CA873505	124	A>S		No	ClinGen ExAC gnomAD
CA873503 rs747883707	125	A>T		No	ClinGen ExAC gnomAD
CA340574001 rs1311430474	130	V>A		No	ClinGen TOPMed gnomAD
rs1453922708 CA340574004	130	V>M		No	ClinGen gnomAD
rs778831660 CA873502	131	G>D		No	ClinGen ExAC gnomAD
rs928116304 CA23069467	132	C>S		No	ClinGen TOPMed gnomAD
rs202227786 CA23069466	134	L>V		No	ClinGen 1000Genomes
rs1298343136 CA340573969	135	F>C		No	ClinGen TOPMed
CA340573967 rs1467153337	135	F>L		No	ClinGen gnomAD
CA340573973 rs1369326077	135	F>L		No	ClinGen Ensembl
rs1361516644 CA340573946	139	I>L		No	ClinGen gnomAD
CA873500 rs753858581	139	I>T		No	ClinGen ExAC gnomAD
rs375354068 CA340573911	143	F>L		No	ClinGen gnomAD
rs1423657232 CA340573902	145	D>N		No	ClinGen gnomAD
CA23069464 rs982341573	151	I>T		No	ClinGen TOPMed gnomAD
COSM911057 rs749957963 CA873497	153	R>C	Variant assessed as Somatic; 0.0 impact. large_intestine endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD
COSM341215 CA873496 rs778042742	153	R>H	lung [Cosmic]	No	ClinGen cosmic curated ExAC gnomAD
rs761614114 CA873495	157	H>N		No	ClinGen ExAC TOPMed gnomAD
rs775715678 CA873494	161	V>A		No	ClinGen ExAC TOPMed gnomAD
rs765676648 CA873493	163	N>S		No	ClinGen ExAC TOPMed gnomAD
CA340573779 rs1343563966	164	P>A		No	ClinGen TOPMed
TCGA novel	165	D>N	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1295684191 CA340573766	166	F>I		No	ClinGen gnomAD
CA873490 rs771463266	168	Q>E		No	ClinGen ExAC gnomAD
CA873489 rs747029264	172	S>P		No	ClinGen ExAC gnomAD
CA23069463 rs941431841	172	S>Y		No	ClinGen Ensembl
rs1454051997 CA340573705	174	G>D		No	ClinGen gnomAD
rs1390388028 CA340573692	176	I>L		No	ClinGen TOPMed gnomAD
rs1390388028 CA340573694	176	I>V		No	ClinGen TOPMed gnomAD
CA873486 rs200887319	178	N>K		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
rs1162287595 CA340573676	178	N>T		No	ClinGen gnomAD
rs778546686 CA873485	180	R>G		No	ClinGen ExAC gnomAD
CA340573663 rs1189598398	180	R>K		No	ClinGen gnomAD
CA340573620 rs1486857859	186	S>G		No	ClinGen TOPMed gnomAD
rs756131844 CA873481	186	S>R		No	ClinGen ExAC gnomAD
CA873480 rs749937717	187	K>E		No	ClinGen ExAC gnomAD
rs1191799496 CA340573607	188	V>I		No	ClinGen TOPMed
rs1433955746 CA340573583	191	A>S		No	ClinGen TOPMed
rs1802023 CA23069431	192	R>S		No	ClinGen Ensembl
rs756051843 CA340573557	193	K>M		No	ClinGen gnomAD
CA23069430 rs756051843	193	K>T		No	ClinGen gnomAD
rs751063721 CA873459	204	M>V		No	ClinGen ExAC gnomAD
CA340573474 rs1179859017	205	Y>C		No	ClinGen gnomAD
CA340573460 rs1238026781	207	M>T		No	ClinGen TOPMed
rs777419822 CA873458	208	L>M		No	ClinGen ExAC TOPMed gnomAD
CA23068195 rs758068290	212	L>I		No	ClinGen ExAC TOPMed gnomAD
CA340573086 rs1569868707	213	Y>S		No	ClinGen Ensembl
CA873437 rs756427754	215	Q>H		No	ClinGen ExAC
CA873436 rs750788245	216	A>S		No	ClinGen ExAC gnomAD
CA340573062 rs1316309327	217	R>C		No	ClinGen gnomAD
CA873435 rs150738833	217	R>H	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ESP ExAC NCI-TCGA TOPMed gnomAD
CA873433 rs751654402 CA340573053	218	F>L		No	ClinGen ExAC TOPMed gnomAD
CA873432 rs199497649	219	T>S		No	ClinGen 1000Genomes ExAC
TCGA novel	220	W>*	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA340573037 rs1161585309	221	R>*	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed gnomAD
CA873431 rs763212888 COSM137771	221	R>Q	skin [Cosmic]	No	ClinGen cosmic curated ExAC TOPMed gnomAD
TCGA novel	222	G>A	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	222	G>R	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA340573020 rs1455419973	224	R>C		No	ClinGen TOPMed
CA873430 rs775806317	224	R>H		No	ClinGen ExAC TOPMed gnomAD
rs1253696312 CA340573014	225	L>P		No	ClinGen gnomAD
rs1189328803 CA340573016	225	L>V		No	ClinGen gnomAD
rs1238767447 CA340573010	226	L>F		No	ClinGen gnomAD
rs1445859998 CA340573004	227	R>Q		No	ClinGen gnomAD
rs765589454 CA873429	227	R>W		No	ClinGen ExAC gnomAD
rs1210159493 CA340572966	233	T>N		No	ClinGen TOPMed gnomAD
rs759339810 CA873428	234	L>W		No	ClinGen ExAC TOPMed gnomAD
rs1272302943 CA340572951	235	I>M		No	ClinGen gnomAD
CA873426 rs770890192	236	M>T		No	ClinGen ExAC gnomAD
CA873427 rs776584476	236	M>V		No	ClinGen ExAC gnomAD
CA23068193 rs944245577	238	A>G		No	ClinGen TOPMed
CA23068194 rs1002779920	238	A>S		No	ClinGen TOPMed
CA23068192 rs746989646	240	Y>*		No	ClinGen ExAC gnomAD
CA340572918 rs1269603920	240	Y>C	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
CA873424 rs772751531	241	T>M	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
rs778468459 CA873421	246	V>I		No	ClinGen ExAC TOPMed gnomAD
TCGA novel	247	S>*	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs754638009 CA873420	252	H>Y		No	ClinGen ExAC gnomAD
CA873419 rs746216456	253	P>A		No	ClinGen ExAC gnomAD
rs1418008908 CA340572831	254	S>G		No	ClinGen gnomAD
rs1167794110 CA340572803	258	A>S		No	ClinGen gnomAD
CA873418 rs141276133	261	A>V		No	ClinGen ESP ExAC TOPMed gnomAD
rs1049124797 CA23068190	263	G>A		No	ClinGen TOPMed gnomAD
CA873417 rs757751099	264	A>D		No	ClinGen ExAC
rs868560033 CA340572766	264	A>S		No	ClinGen gnomAD
rs868560033 CA23068189	264	A>T		No	ClinGen gnomAD
rs1222048489 CA340572750	267	A>T		No	ClinGen TOPMed gnomAD
rs372335333 CA873413	268	C>Y		No	ClinGen ESP ExAC TOPMed gnomAD
rs1291703103 CA340572734	269	C>F		No	ClinGen TOPMed
rs759898320 CA873411	270	I>M		No	ClinGen ExAC gnomAD
rs765501405 CA873412	270	I>T	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
rs182999910 CA873392	274	V>M		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
rs1557494763 CA340572676	276	D>A		No	ClinGen Ensembl
CA340572675 rs1557494763	276	D>G		No	ClinGen Ensembl
CA23066630 rs899202466	276	D>H		No	ClinGen TOPMed gnomAD
CA340572648 rs1422822047	280	T>A		No	ClinGen gnomAD
rs17850456 CA873391	282	T>K		No	ClinGen ESP ExAC TOPMed gnomAD
rs17850456 CA873390	282	T>M		No	ClinGen ESP ExAC TOPMed gnomAD
CA23066629 rs890556930	283	T>A		No	ClinGen TOPMed gnomAD
rs150216828 CA873388	283	T>M		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA340572625 rs1405600033	284	L>F		No	ClinGen gnomAD
CA340572624 rs1176411561	284	L>R		No	ClinGen TOPMed gnomAD
rs746192689 CA873386	285	S>C		No	ClinGen ExAC TOPMed gnomAD
CA23066628 rs746192689	285	S>F		No	ClinGen ExAC TOPMed gnomAD
CA340572616 rs1208590537	286	L>V		No	ClinGen gnomAD
rs1557494725 CA340572608	287	P>R		No	ClinGen Ensembl
rs762473321 CA873385	288	A>G		No	ClinGen ExAC gnomAD
CA340572592 rs1212594668	290	A>G		No	ClinGen gnomAD
rs575915994 CA873384	290	A>T		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
rs146593813 CA873383	291	I>V		No	ClinGen ESP ExAC TOPMed gnomAD
rs1229420952 CA340572581	292	R>L		No	ClinGen gnomAD
rs1229420952 CA340572583	292	R>Q		No	ClinGen gnomAD
rs747279885 COSM911056 CA873382	292	R>W	Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD
CA340572564 rs1404033545	295	I>L		No	ClinGen TOPMed
CA23066625 rs914138911	298	P>S		No	ClinGen TOPMed gnomAD
CA873381 rs147388964	299	V>M		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA340572533 rs1286657067	300	D>A		No	ClinGen TOPMed
rs772704217 CA873380	300	D>N		No	ClinGen ExAC
rs1414687048 CA340572517	302	I>T		No	ClinGen gnomAD
TCGA novel	304	R>K	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs917338023 CA23066624	305	N>K		No	ClinGen Ensembl
CA340572495 rs1557494692	305	N>S		No	ClinGen Ensembl
CA340572480 rs867699788	307	H>L		No	ClinGen TOPMed
CA23066623 rs867699788	307	H>R		No	ClinGen TOPMed
CA23066622 rs935658742	309	N>D		No	ClinGen TOPMed
TCGA novel	310	M>T	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA340572461 rs1304245519	310	M>V		No	ClinGen Ensembl
rs779117993 CA873377	311	M>T		No	ClinGen ExAC

No associated diseases with O14495

1 regional properties for O14495

Type	Name	Position	InterPro Accession
domain	Phosphatidic acid phosphatase type 2/haloperoxidase	130 - 276	IPR000326

Functions

		Description
EC Number	3.1.3.4	Phosphoric monoester hydrolases
Subcellular Localization	Cell membrane ; Multi-pass membrane protein Basolateral cell membrane ; Multi-pass membrane protein Endoplasmic reticulum membrane ; Multi-pass membrane protein Endoplasmic reticulum-Golgi intermediate compartment membrane ; Multi-pass membrane protein Golgi apparatus membrane ; Multi-pass membrane protein Golgi apparatus, trans-Golgi network membrane ; Multi-pass membrane protein Membrane raft ; Multi-pass membrane protein	Cycles between the endoplasmic reticulum and the Golgi
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

13 GO annotations of cellular component

Name	Definition
adherens junction	A cell-cell junction composed of the epithelial cadherin-catenin complex. The epithelial cadherins, or E-cadherins, of each interacting cell extend through the plasma membrane into the extracellular space and bind to each other. The E-cadherins bind to catenins on the cytoplasmic side of the membrane, where the E-cadherin-catenin complex binds to cytoskeletal components and regulatory and signaling molecules.
basolateral plasma membrane	The region of the plasma membrane that includes the basal end and sides of the cell. Often used in reference to animal polarized epithelial membranes, where the basal membrane is the part attached to the extracellular matrix, or in plant cells, where the basal membrane is defined with respect to the zygotic axis.
endoplasmic reticulum exit site	An endoplasmic reticulum part at which COPII-coated vesicles are produced.
endoplasmic reticulum membrane	The lipid bilayer surrounding the endoplasmic reticulum.
endoplasmic reticulum-Golgi intermediate compartment membrane	The lipid bilayer surrounding any of the compartments of the endoplasmic reticulum (ER)-Golgi intermediate compartment system.
Golgi apparatus	A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways.
Golgi membrane	The lipid bilayer surrounding any of the compartments of the Golgi apparatus.
integral component of membrane	The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
integral component of plasma membrane	The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
membrane raft	Any of the small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes. Small rafts can sometimes be stabilized to form larger platforms through protein-protein and protein-lipid interactions.
plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.
trans-Golgi network	The network of interconnected tubular and cisternal structures located within the Golgi apparatus on the side distal to the endoplasmic reticulum, from which secretory vesicles emerge. The trans-Golgi network is important in the later stages of protein secretion where it is thought to play a key role in the sorting and targeting of secreted proteins to the correct destination.

5 GO annotations of molecular function

Name	Definition
ceramide-1-phosphate phosphatase activity	Catalysis of the reaction: ceramide-1-phosphate + H2O = ceramide+ phosphate.
integrin binding	Binding to an integrin.
lipid phosphatase activity	Catalysis of the reaction: a phospholipid + H2O = a lipid + phosphate.
phosphatidate phosphatase activity	Catalysis of the reaction: a 1,2-diacylglycerol 3-phosphate + H2O = a 1,2-diacyl-sn-glycerol + phosphate.
sphingosine-1-phosphate phosphatase activity	Catalysis of the reaction: sphingosine 1-phosphate + H2O = sphingosine + phosphate.

23 GO annotations of biological process

Name	Definition
Bergmann glial cell differentiation	The process in which neuroepithelial cells of the neural tube give rise to Brgmann glial cells, specialized bipotential progenitors cells of the cerebellum. Differentiation includes the processes involved in commitment of a cell to a specific fate.
blood vessel development	The process whose specific outcome is the progression of a blood vessel over time, from its formation to the mature structure. The blood vessel is the vasculature carrying blood.
canonical Wnt signaling pathway	The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes. In this pathway, the activated receptor signals via downstream effectors that result in the inhibition of beta-catenin phosphorylation, thereby preventing degradation of beta-catenin. Stabilized beta-catenin can then accumulate and travel to the nucleus to trigger changes in transcription of target genes.
cell-cell adhesion mediated by integrin	The attachment of one cell to another cell via an integrin, a heterodimeric adhesion receptor formed by the non-covalent association of particular alpha and beta subunits.
ceramide metabolic process	The chemical reactions and pathways involving ceramides, any N-acylated sphingoid.
gastrulation with mouth forming second	A gastrulation process in which the initial invagination becomes the anus and the mouth forms second.
homotypic cell-cell adhesion	The attachment of a cell to a second cell of the identical type via adhesion molecules.
integrin-mediated signaling pathway	The series of molecular signals initiated by an extracellular ligand binding to an integrin on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription.
negative regulation of protein phosphorylation	Any process that stops, prevents or reduces the rate of addition of phosphate groups to amino acids within a protein.
phospholipid dephosphorylation	The process of removing one or more phosphate groups from a phosphorylated lipid, any member of a group of substances soluble in lipid solvents but only sparingly soluble in aqueous solvents.
phospholipid metabolic process	The chemical reactions and pathways involving phospholipids, any lipid containing phosphoric acid as a mono- or diester.
positive regulation of cell-cell adhesion	Any process that activates or increases the rate or extent of cell adhesion to another cell.
positive regulation of DNA-binding transcription factor activity	Any process that activates or increases the frequency, rate or extent of activity of a transcription factor, any factor involved in the initiation or regulation of transcription.
positive regulation of endothelial cell migration	Any process that increases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.
positive regulation of peptidyl-tyrosine phosphorylation	Any process that activates or increases the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.
protein stabilization	Any process involved in maintaining the structure and integrity of a protein and preventing it from degradation or aggregation.
regulation of sphingolipid mediated signaling pathway	Any process that modulates the frequency, rate or extent of sphingolipid signaling.
regulation of Wnt signaling pathway	Any process that modulates the frequency, rate or extent of the activity of the Wnt signal transduction pathway.
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	The directed movement of substances from the Golgi back to the endoplasmic reticulum, mediated by vesicles bearing specific protein coats such as COPI or COG.
signal transduction	The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.
sphingolipid biosynthetic process	The chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).
sphingosine metabolic process	The chemical reactions and pathways involving sphingosine (sphing-4-enine), trans-D-erytho-2-amino-octadec-4-ene-1,3-diol, a long chain amino diol sphingoid base that occurs in most sphingolipids in animal tissues.
wound healing	The series of events that restore integrity to a damaged tissue, following an injury.

6 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
Q8TBJ4	PLPPR1	Phospholipid phosphatase-related protein type 1	Homo sapiens (Human)	PR
Q8BFZ2	Plppr1	Phospholipid phosphatase-related protein type 1	Mus musculus (Mouse)	PR
Q99JY8	Plpp3	Phospholipid phosphatase 3	Mus musculus (Mouse)	PR
Q6WAY2	Plppr1	Phospholipid phosphatase-related protein type 1	Rattus norvegicus (Rat)	PR
P97544	Plpp3	Phospholipid phosphatase 3	Rattus norvegicus (Rat)	PR
A4II83	plppr1	Phospholipid phosphatase-related protein type 1	Xenopus tropicalis (Western clawed frog) (Silurana tropicalis)	PR

10	20	30	40	50	60
MQNYKYDKAI	VPESKNGGSP	ALNNNPRRSG	SKRVLLICLD	LFCLFMAGLP	FLIIETSTIK
70	80	90	100	110	120
PYHRGFYCND	ESIKYPLKTG	ETINDAVLCA	VGIVIAILAI	ITGEFYRIYY	LKKSRSTIQN
130	140	150	160	170	180
PYVAALYKQV	GCFLFGCAIS	QSFTDIAKVS	IGRLRPHFLS	VCNPDFSQIN	CSEGYIQNYR
190	200	210	220	230	240
CRGDDSKVQE	ARKSFFSGHA	SFSMYTMLYL	VLYLQARFTW	RGARLLRPLL	QFTLIMMAFY
250	260	270	280	290	300
TGLSRVSDHK	HHPSDVLAGF	AQGALVACCI	VFFVSDLFKT	KTTLSLPAPA	IRKEILSPVD
310
IIDRNNHHNM	M